BioAffinity Technologies today announced it appointed Michael Dougherty as chief financial officer, effective immediately.
Dougherty will report directly to President and CEO Maria Zannes. He has more than 20 years of experience in financial management and business strategy. Former CFO Michael Edwards will remain as a consultant to ensure a smooth transition.
“We are delighted to welcome Mike to our executive leadership team. He brings a tremendous skill set developed in senior positions at Amazon and Russell Investments. His expertise in financial management will play an important role in the nationwide commercial rollout of CyPath Lung,” Zannes said in a news release. “His experience in strategy development and M&A will be crucial as we expand the CyPath brand into other indications and pursue therapeutics opportunities. I look forward to his input and leadership as we increase visibility for our Company among investors, analysts and the broader financial…